系统综述与Meta分析:炎症性肠病单药或联合治疗中免疫调节剂或生物制剂撤药的影响
该系统综述与Meta分析检索五个数据库,纳入10项随机对照试验(587例患者)及另外9项研究,评估克罗恩病或溃疡性结肠炎患者停用生物制剂或免疫调节剂后的复发率。停用免疫调节剂单药治疗在克罗恩病中随访24个月内复发风险显著高于持续治疗(RR=2.06,95%CI 1.53-2.77),溃疡性结肠炎中无显著差异(RR=1.39,95%CI 0.85-2.26)。从联合治疗中停用免疫调节剂未显示复发风险高于继续两药联合(RR=1.30,95%CI 0.81-2.08)。
要点
- 克罗恩病停用免疫调节剂单药后24个月内复发风险显著高于持续治疗(RR=2.06,95%CI 1.53-2.77)。
- 溃疡性结肠炎停用免疫调节剂单药后复发风险与持续治疗无显著差异(RR=1.39,95%CI 0.85-2.26)。
- 从生物制剂联合治疗中停用免疫调节剂未显示复发风险增高(RR=1.30,95%CI 0.81-2.08)。
核心结论
- 克罗恩病患者应继续免疫调节剂单药治疗作为首选方案,尽管长期毒性是顾虑。
- 溃疡性结肠炎及含生物制剂的联合方案需进一步随机对照试验。
研究设计与样本
- 系统综述与Meta分析,检索五个数据库,纳入评估克罗恩病或溃疡性结肠炎撤药后复发的研究。
- Meta分析纳入10项随机对照试验共587例患者,另9项研究纳入系统综述。
主要发现
- 克罗恩病停用免疫调节剂单药后24个月内复发风险显著高于持续治疗(RR=2.06,95%CI 1.53-2.77)。
- 溃疡性结肠炎停用免疫调节剂单药后复发风险与持续治疗无显著差异(RR=1.39,95%CI 0.85-2.26)。
- 从生物制剂联合治疗中停用免疫调节剂未显示复发风险高于继续两药联合(RR=1.30,95%CI 0.81-2.08)。
- 试验序贯分析提示,类似设计的进一步研究不太可能改变克罗恩病停用免疫调节剂单药后复发率显著关联的结论。
- 停用生物制剂单药后复发率升高,而从联合方案中停用生物制剂后结果矛盾。
临床怎么用
- 作者认为,克罗恩病患者应继续免疫调节剂单药治疗作为首选方案,尽管长期毒性是顾虑。
- 作者认为,溃疡性结肠炎及含生物制剂的联合方案需进一步随机对照试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Withdrawal of treatment is a common therapeutic problem in patients with long-standing remission of inflammatory bowel disease. AIMS: To evaluate the relapse rate in patients with quiescent inflammatory bowel disease after cessation of biologic or immunomodulator therapy. METHODS: We searched five databases for studies evaluating disease relapse after withdrawal of monotherapy or a drug from combination therapy in Crohn's disease or ulcerative colitis. In meta-analysis, risk ratios (RR) were calculated with 95% confidence intervals (CI). RESULTS: Ten randomised controlled trials (587 patients) were included in the meta-analysis, and another nine studies in systematic review. Withdrawal of immunomodulator monotherapy resulted in a significantly higher risk of relapse within 24 months of follow-up compared to ongoing therapy in Crohn's disease, but not in ulcerative colitis (RR = 2.06, CI: 1.53-2.77 and RR = 1.39, CI: 0.85-2.26, respectively). Trial sequential analysis indicated that further studies with similar design are unlikely to change the significant association on relapse rates after withdrawing immunomodulator monotherapy in patients with Crohn's disease. Discontinuation of an immunomodulator from combination with biologics did not show a higher risk of relapse than continuation of both drugs (RR = 1.30, CI: 0.81-2.08). The relapse rate increased after withdrawal of biologic monotherapy, whereas contradictory results were observed after biologic withdrawal from combination regimens. CONCLUSION: Continuing immunomodulator monotherapy should remain the preferred approach among patients with Crohn's disease, although long-term toxicity is a concern. Further randomised controlled trials are warranted in ulcerative colitis and on combination regimens including biologics.
引用
- Dohos D, Hanák L, Szakács Z, et al. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 33249621. doi:10.1111/apt.16182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。